top of page
Home
Solutions
Treatment Selection
LiquidHALLMARK®
Screening & Health Risk Assessment
CardioHemeRISK™
Treatment Selection
LiquidHALLMARK®
Screening & Health Risk Assessment
CardioHemeRISK™
Communities
Oncologists
Patients
Insurers
Investors
Oncologists
Patients
Insurers
Investors
Knowledge Center
Publications
News & Updates
Patient Stories
Webinars
Case Studies
Publications
News & Updates
Patient Stories
Webinars
Case Studies
About Us
About Lucence
Leadership
Careers
Contact Us
About Lucence
Leadership
Careers
Contact Us
Mobile menu (US)
Portal Login
Close
Home
Solutions
Screening and Health Risk Assessment
LucenceINSIGHT®
CardioHemeRISK™
LucenceLONGEVITY™
Treatment Selection
LiquidHALLMARK® & LiquidMARK™
LiquidSCREEN™ Lung
HemeMARK™
UNITED™ 600
UNITED™ CNS
Rapid TissueMARK™
NPC GOLD™
Hereditary Risk Assessment
Lumi Series
Treat Response Monitoring
LucenceMONITOR™
Screening and Health Risk Assessment
LucenceINSIGHT®
CardioHemeRISK™
LucenceLONGEVITY™
Treatment Selection
LiquidHALLMARK® & LiquidMARK™
LiquidSCREEN™ Lung
HemeMARK™
UNITED™ 600
UNITED™ CNS
Rapid TissueMARK™
NPC GOLD™
Hereditary Risk Assessment
Lumi Series
Treat Response Monitoring
LucenceMONITOR™
Communities
Primary Care Doctors
Oncologists
Patients
Investors
Primary Care Doctors
Oncologists
Patients
Investors
Knowledge Center
Publications
News & Updates
Patient Stories
Webinars
Case Studies
Publications
News & Updates
Patient Stories
Webinars
Case Studies
About Lucence
About Lucence
Leadership
Careers
Contact Us
About Lucence
Leadership
Careers
Contact Us
Mobile menu (RoW)
Close
Solutions
篩查與健康風險評估
LucenceINSIGHT®
CardioHemeRISK™
LucenceLONGEVITY™
Menu
Close
治療方案選擇
LiquidHALLMARK® & LiquidMARK™
LiquidSCREEN™ Lung
HemeMARK™
UNITED™ 600
UNITED™ CNS
Rapid TissueMARK™
NPC GOLD™
Menu
Close
遺傳風險評估
Lumi Series
Menu
Close
治療反應監測
LucenceMONITOR™
Menu
Close
治療方案選擇
LiquidHALLMARK®
Menu
Close
Communities
社群
Oncologists
Patients
Insurers
Investors
Menu
Close
社群
Primary Care Doctors
Oncologists
Patients
Investors
Menu
Close
Knowledge Center
知識資源中心
Publications
News & Updates
Patient Stories
Webinars
Case Studies
Menu
Close
About Us
關於我們
About Lucence
Leadership
Careers
Contact Us
Menu
Close
Menu
Close
Solutions
篩查與健康風險評估
CardioHemeRISK™
Menu
Close
治療方案選擇
LiquidHALLMARK®
Menu
Close
Communities
社群
Oncologists
Patients
Insurers
Investors
Menu
Close
Knowledge Center
知識資源中心
Publications
News & Updates
Patient Stories
Webinars
Case Studies
Menu
Close
About Us
關於我們
About Lucence
Leadership
Careers
Contact Us
Menu
Close
Menu
Close
Portal Login
Publications
Filter by:
Year
Conference/Journal name
Publications
2023年9月10日
Plasma Cell-free RNA Sequencing Enables Sensitive Detection of Lung Cancer
Read More
Plasma Cell-free RNA Sequencing Enables Sensitive Detection of Lung Cancer
Publications
2023年5月31日
Assessing the utility of liquid biopsy for determining actionable genetic mutations among indigenous Ghanaian women with metastatic Breast Cancer
Read More
Assessing the utility of liquid biopsy for determining actionable genetic mutations among indigenous Ghanaian women with metastatic Breast Cancer
Publications
2023年5月31日
Liquid biopsy in combination with PET/CT versus PET/CT alone in diagnosis of lung cancer in small nodules.
Read More
Liquid biopsy in combination with PET/CT versus PET/CT alone in diagnosis of lung cancer in small nodules.
Publications
2023年5月31日
Longitudinal tracking of ALK-positive lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA in the BRIGHTSTAR clinical trial
Read More
Longitudinal tracking of ALK-positive lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA in the BRIGHTSTAR clinical trial
Publications
2023年5月31日
Development and evaluation of a multi-cancer screening (MCS) test for cancers common in Asia.
Read More
Development and evaluation of a multi-cancer screening (MCS) test for cancers common in Asia.
Publications
2023年5月31日
Combining plasma and tissue next-generation sequencing provides optimal treatment selection for metastatic NSCLC: a comparative study.
Read More
Combining plasma and tissue next-generation sequencing provides optimal treatment selection for metastatic NSCLC: a comparative study.
Publications
2023年5月1日
Complete mutation concordance with amplicon-based NGS between peripheral blood and bone marrow at 0.5% VAF threshold
Read More
Complete mutation concordance with amplicon-based NGS between peripheral blood and bone marrow at 0.5% VAF threshold
Publications
2023年3月1日
Clinical Validation of a Promising New Amplicon-Based Liquid Biopsy Platform for Detection of Guideline Recommended Biomarkers in Metastatic NSCLC
Read More
Clinical Validation of a Promising New Amplicon-Based Liquid Biopsy Platform for Detection of Guideline Recommended Biomarkers in Metastatic NSCLC
Publications
2022年11月1日
Liquid biopsy NGS test identifies actionable DNA mutations from CSF specimens of lung cancer patients
Read More
Liquid biopsy NGS test identifies actionable DNA mutations from CSF specimens of lung cancer patients
Go
Go
1
/
8
Go
Go
Like
bottom of page